Active, not recruitingPhase 3NCT04590963
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Roger B Cohen, MD, MDAbramson Cancer Center, Perelman Center for Advanced Medicine
- Intervention
- Monalizumab(drug)
- Enrollment
- 370 enrolled
- Eligibility
- 18-130 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- Research Site, Tucson, Arizona, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Westwood, Kansas, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, Ann Arbor, Michigan, United States
- Research Site, Rochester, Minnesota, United States
- Research Site, St Louis, Missouri, United States
- Research Site, Las Vegas, Nevada, United States
- Research Site, New York, New York, United States
- Research Site, Charlotte, North Carolina, United States
- Research Site, Winston-Salem, North Carolina, United States
- Research Site, Columbus, Ohio, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Pittsburgh, Pennsylvania, United States
- Research Site, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Innate Pharma
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04590963 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- RECRUITINGPHASE2, PHASE3NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerNational Cancer Institute (NCI)
See all trials for Squamous cell carcinoma of the hypopharynx →